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Oliveira EM, Casarini DE, Krieger JE, Brum PC. The role of local
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Regul Integr Comp Physiol 294: R26–R32, 2008. First published
October 31, 2007; doi:10.1152/ajpregu.00424.2007.—Sympathetic
hyperactivity (SH) and renin angiotensin system (RAS) activation are
commonly associated with heart failure (HF), even though the relative
contribution of these factors to the cardiac derangement is less
understood. The role of SH on RAS components and its consequences
for the HF were investigated in mice lacking 2A and 2C adreno-
ceptor knockout (2A/2CARKO) that present SH with evidence of
HF by 7 mo of age. Cardiac and systemic RAS components and
plasma norepinephrine (PN) levels were evaluated in male adult mice
at 3 and 7 mo of age. In addition, cardiac morphometric analysis,
collagen content, exercise tolerance, and hemodynamic assessments
were made. At 3 mo, 2A/2CARKO mice showed no signs of HF,
while displaying elevated PN, activation of local and systemic RAS
components, and increased cardiomyocyte width (16%) compared
with wild-type mice (WT). In contrast, at 7 mo, 2A/2CARKO mice
presented clear signs of HF accompanied only by cardiac activation of
angiotensinogen and ANG II levels and increased collagen content
(twofold). Consistent with this local activation of RAS, 8 wk of ANG
II AT1 receptor blocker treatment restored cardiac structure and
function comparable to the WT. Collectively, these data provide direct
evidence that cardiac RAS activation plays a major role underlying
the structural and functional abnormalities associated with a genetic
SH-induced HF in mice.
sympathetic nervous system; AT1 receptor blocker; 2a/2c adrener-
gic knockout mice
HEART FAILURE (HF) IS A PROGRESSIVE disorder that involves
reduced cardiac output associated with neurohumoral changes,
including activation of renin angiotensin (RAS) and sympa-
thetic nervous systems (2, 4). The neurohumoral imbalance
leads to cardiac dysfunction and hypertrophy, which culmi-
nates in cardiac remodeling and development of HF. Although
the mechanisms for the transition of cardiac hypertrophy to HF
are poorly understood, increased cardiac ANG II has been
observed in a clinical course of human HF and related to a
progressive impairment of ventricular function (39).
The RAS plays a prominent role in cardiac remodeling
during HF development, since increased cardiac ANG II levels
lead to cardiac myocyte hypertrophy and myocardial fibrosis
(8, 21, 25). It is well known that all components required for
ANG II production are available in the heart, and cardiac ANG
II formation seems to be regulated independently of circulating
RAS (17, 33, 43). Indeed, mechanical and humoral regulation
of cardiac ANG II production in HF includes increased cardiac
wall tension and sympathetic hyperactivity (9). The latter, by
activating -adrenergic receptors (-AR), stimulates renin and
angiotensinogen (Ao) synthesis in fibroblasts and Ao synthesis
in cardiac myocytes. Despite evidence for positive feedback
between -AR system and RAS in producing cardiac pleiotro-
pic peptides as ANG II (14, 21, 29), to date, there are no data
on the role of sympathetic hyperactivity on cardiac RAS
components in a setting of developing HF.
We previously reported that mice lacking both 2A/2C
adrenergic receptors (2A/2C ARKO) develop sympathetic
hyperactivity-induced HF, which is related to cardiac dysfunc-
tion and remodeling with increased mortality rate at 7 mo of
age (3, 34). In contrast, at 3 mo of age 2A/2C, ARKO mice
present preserved cardiac function with no significant mortality
rate when compared with age-matched wild-type mice (27).
Therefore, these mice provide a good model system for study-
ing the influence of sympathetic hyperactivity on cardiac RAS
activation in different stages of cardiac disease.
The present investigation was undertaken to establish the
relationship of sympathetic hyperactivity and RAS compo-
nents during the development of HF and the relative contribu-
tion of the latter to the cardiac structural and functional
abnormalities observed in advanced stage of a genetic model of
sympathetic hyperactivity-induced HF in mice.
METHODS
Study population. A cohort of male congenic 2A/2CARKO mice
in a C57BL6/J genetic background and their wild-type controls (WT)
were studied at 3 and 7 mo of age. At 3 mo of age, 2A/2CARKO
mice display normal cardiac function (27), but at 7 mo of age, they
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present severe cardiac dysfunction associated with exercise intoler-
ance and increased mortality rate (3, 34). Mice were maintained in a
12:12-h light-dark cycle and temperature-controlled environment
(22°C) with free access to standard laboratory chow (Nuvital Nutri-
entes S/A, Curitiba, PR Brazil) and tap water. This study was
performed according to ethical principles in animal research adopted
by Brazilian College of Animal Experimentation (www.cobea.org.br).
In addition, this study was approved by the University of Sa˜o Paulo
Ethical Committee (CEP#059).
Graded treadmill exercise test. Exercise capacity, estimated by
total distance run, is a widespread method of characterizing cardiac
dysfunction in rodents and humans with HF (30, 34). Exercise
tolerance was evaluated using a graded treadmill exercise protocol for
mice as previously described (13). Briefly, after being adapted to
treadmill exercises over a week (10 min of exercise session), mice
were placed in the exercise streak and allowed to acclimatize for at
least 30 min. Intensity of exercise was increased by 3 m/min (6–33
m/min) every 3 min at 0% grade until exhaustion.
Cardiovascular measurements. Heart rate and blood pressure were
determined noninvasively using a computerized tail-cuff system (BP
2000 Visitech Systems) described elsewhere (19). Mice were accli-
matized to the apparatus during daily sessions over 4 days, one week
before starting the experimental period.
Structural analysis. All mice were killed and their tissues were
harvested. Cardiac chambers were then fixed by immersion in 4%
buffered formalin and embedded in paraffin for routine histologic
processing. Sections (4 m) were stained with hematoxylin and eosin
for examination by light microscopy. Only nucleated cardiac myo-
cytes from areas of transversely cut muscle fibers were included in the
analysis. Quantification of left ventricular fibrosis was achieved by
Sirius red staining. Cardiac myocyte width and ventricular fibrosis
were measured in the left ventricle free wall with a computer-assisted
morphometric system (Leica Quantimet 500, Cambridge, UK).
Immunohistochemistry. Cardiac samples for ANG II immunohis-
tochemistry were obtained from WT and 2A/2CARKO mice at 3
and 7 mo of age. Left ventricle sections were deparaffinized in xylene
and rehydrated in ethanol. Retrieval of ANG II immunoreactivity was
obtained by incubating sections in citrate buffer (0.01 M, pH 6.0) with
further heating for 5 min in microwave oven. The presence of ANG
II was evaluated in left ventricle tissue using anti-ANG II rabbit
antiserum (1:400; Penı´nsula, Belmont, CA) (15). The antigen was
marked by fast red dye, and the specificity of the secondary antibody
was established in positive and negative controls. Images were ob-
tained with a computer-assisted morphometric system (Leica Quanti-
met 500, Cambridge, UK). The number of positive signal in cardio-
myocyte was evaluated and expressed as cells of ANG II/mm2.
Angiotensin-converting enzyme activity assay. Cardiac angioten-
sin-converting enzyme (ACE) activity was determined via fluoromet-
ric assay of cardiac tissue samples from 3- and 7-mo-old WT and
2A/2CARKO mice, frozen in liquid nitrogen and stored at70°C (1).
Briefly, the homogenate supernatant was incubated for 30 min at 37°C
with a fluorogenic substrate containing 10 M Abz-FRK(Dnp)P-OH
(Abz is o-aminobenzoic acid; DnP is dinitrophenyl) in 0.1 M Tris HCl
buffer, 50 mM NaCl, and 10 mM ZnCl2, pH 7.0. Hydrolysis rate of the
intramoleculary quenched fluorogenic substrate Abz-FRK-(Dnp)P-OH
was assessed by using a fluorometer to measure fluorescence at em 
420 nm (ex  320 nm). The slope was converted into micromoles of
substrate hydrolyzed per minute, based on the calibration curve
obtained from complete hydrolysis of each peptide.
Plasma renin activity assay. Plasma renin activity was determined
in 3- and 7-mo-old WT and 2A/2CARKO mice by radioimmuno-
assay using commercially available kits, according to the manufac-
turer’s instructions (Renin Kit, CISBIO International, Bagnols,
France).
Catecholamines measurements. Plasma noradrenaline was mea-
sured by HPLC using ion-pair reverse-phase chromatography cou-
pled with electrochemical detection (0.5 V), as described by Monte
et al. (28).
Immunoblot. Immunoblots of 3- and 7-mo-old WT and 2A/
2CARKO of heart and kidney homogenates were performed according
to Towbin et al. (42). Briefly, liquid nitrogen frozen tissues were homog-
enized in a buffer containing 1 mM EDTA, 1 mM EGTA, 2 mM MgCl2,
5 mM KCl, 25 mM HEPES (pH.7.5), 100 M PMSF, 2 mM DTT, 1%
Triton X-100, and protease inhibitor cocktail (1:100, Sigma-Aldrich;
St. Louis, MO). Samples were loaded and subjected to SDS-PAGE in
polyacrylamide gels (10%). After electrophoresis, proteins were elec-
trotransferred to nitrocellulose membrane (Amersham Biosciences;
Piscataway, NJ). Equal loading of samples (60 g) and even transfer
efficiency were monitored with the use of 0.5% Ponceau S staining of
the blotted membrane. The blotted membrane was then incubated in a
blocking buffer (5% nonfat dry milk, 10 mM Tris HCl, pH 7.6, 150
mM NaCl, and 0.1% Tween 20) for 2 h at room temperature and then
incubated overnight at 4°C with rabbit anti-human renin polyclonal
antibody (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA) and
sheep anti-human Ao antibody (1:200; a kind gift from Dr. S. Kumar,
Birmingham, UK). Binding of the primary antibody was detected with
the use of peroxidase-conjugated secondary antibodies (anti-rabbit or
anti-sheep, 1:5,000, for 1.5 h at room temperature) and developed
using enhanced chemiluminescence (Amersham Biosciences) de-
tected by autoradiography. Quantification analysis of blots was per-
formed with the use of Scion Image software (Scion based on
National Institutes of Health ImageJ). Targeted bands were normal-
ized to renal GAPDH.
Real-time RT-PCR. RNA was isolated from heart tissue with
TRIzol reagent (GIBCO, Invitrogen, Carlsbad, CA). RNA concentra-
tion and integrity were assessed; cDNA was synthesized using Su-
perscript III RNase H-RT (Invitrogen) at 42°C for 50 min and
real-time PCR was performed. The primers used for gene amplifica-
tion were Ao sense, 5-CCGAGGATCCTACAATCTGC-3; Ao an-
tisense, 5-TTTGAGTTCGAGGAGGATGC-3; Cyclofilin sense, 5-
AATGCTGGACCAAACACAAA-3; and Cyclofilin antisense, 5-
CCTTCTTTCACCTTCCCAAA-3. Real-time PCR for Ao and
housekeeper gene, cyclofilin were run separately, and amplifications
were performed with an ABI Prism 7700 Sequence Detection System
(Applied Biosystems, Foster City, CA) by using SYBR Green PCR
Master Mix (Applied Biosystems). The results were quantified as
cycle threshold (Ct) values, where Ct is defined as the threshold cycle
of the PCR at which the amplified product is first detected. Expression
was normalized with cyclofilin levels as an endogenous reference.
ANG II AT1 blocker treatment. To test whether increased cardiac
RAS would be functionally involved in ventricular dysfunction and
remodeling of advanced-stage cardiomyopathy, 2A/2CARKO mice
were randomly assigned to receive either saline or ANG II AT1
receptor blocker (ARB, losartan, 10 mg/kg in drinking water) for 8 wk
(from 5 to 7 mo of age). ARB did not change blood pressure, cardiac
function, and structure of WT mice. Therefore, we used only one
control WT group for further comparisons with 2A/2CARKO
groups.
Noninvasive ventricular function was assessed by two-dimensional
guided M-mode echocardiography, in halothane-anesthetized WT and
2A/2CARKO mice, before and after ARB treatment. Briefly, mice
were positioned in the supine position with front paws wide open, and
an ultrasound transmission gel was applied to the precordium. Trans-
thoracic echocardiography was performed using an Acuson Sequoia
model 512 echocardiographer equipped with a 14-MHz linear trans-
ducer. Left ventricle systolic function was estimated by fractional
shortening as follows: fractional shortening (%)  [(LVEDD 
LVESD)/LVEDD]  100, where LVEDD means left ventricular
end-diastolic dimension, and LVESD means left ventricular end-
systolic dimension.
Cardiac myocyte width and ventricular collagen content after ARB
treatment were measured in the left ventricle free wall, as previously
described in Structural analysis.
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Statistical analysis. All values are presented as means 	 SE.
Two-way ANOVA with a post hoc testing by Tukey was used to
compare the effect of genotype (WT and 2A/2CARKO mice) and
cardiomyopathy stage (3 and 7 mo of age) on hemodynamics, cardiac
structure, plasma noradrenaline, exercise tolerance, lung water reten-
tion, and RAS components. The relationship between cardiac Ao and
ANG II levels was assessed by linear regression analysis. One-way
ANOVA with post hoc testing by Tukey was used to compare the
effect of treatment on fractional shortening (FS), LVESD, LVEDD,
cardiomyocyte width, and cardiac fibrosis. Statistical significance was
considered achieved when the value of P was 
0.05.
RESULTS
Effect of sympathetic hyperactivity on hemodynamics, nor-
adrenaline levels, and distance run. Physiological parameters
of WT and 2A/2CARKO mice are presented in Table 1. As
expected, 3- and 7-mo-old 2A/2CARKO mice presented
higher plasma noradrenaline levels than age-matched WT
mice. The increased noradrenaline levels were paralleled by
resting tachycardia in 3- and 7-mo-old 2A/2CARKO mice,
while blood pressure remained unchanged when compared
with age-matched WT mice. At 3 mo of age, distance run and
lung wet/dry ratio of 2A/2CARKO mice were similar to that
observed in age-matched WT mice. In contrast, 7-mo-old
2A/2CARKO displayed exercise intolerance and increased
lung water retention when compared with age-matched WT
mice. This result suggests that 7-mo-old 2A/2CARKO mice
present lung edema, which we previously demonstrated to be
related to an impaired ventricular function (34).
Effect of chronic sympathetic hyperactivity on RAS compo-
nents. It is well recognized that sympathetic hyperactivity
activates other neurohumoral systems, such as RAS (26, 31).
To test whether RAS activity is increased in 2A/2CARKO,
we evaluated cardiac ANG II in 2A/2CARKO mice. As
depicted in Fig. 1A, 3- and 7-mo-old 2A/2CARKO mice
displayed elevated cardiac ANG II levels when compared with
age-matched WT mice. Inasmuch as ANG II induces myocyte
growth, we evaluated cardiac myocyte cross-sectional diameter
by quantitative morphometrical analysis. As shown in Fig. 1B,
3- and 7-mo-old 2A/2CARKO mice displayed significantly
greater cardiac myocyte cross-sectional diameter than age-
matched WT mice. Of interest, cardiac myocyte hypertrophy in
2A/2CARKO mice was paralleled by an increased ventricular
fibrosis at 7 mo of age, represented by a twofold increase in
cardiac collagen content when compared with age-matched
WT mice (Fig. 1C). In contrast, cardiac collagen content of
3-mo-old 2A/2CARKO mice remained unchanged when
compared with age-matched WT mice (Fig. 1C).
To verify the RAS components involved in elevated cardiac
ANG II in our genetic model of sympathetic hyperactivity-
induced cardiomyopathy, we evaluated cardiac ACE activity,
plasma renin activity, and kidney renin expression in 2A/
2CARKO mice (Fig. 2). At 3 mo of age, the augmented
cardiac ANG II levels in 2A/2CARKO mice was associated
with an increased cardiac ACE activity, plasma renin activity,
and renal renin expression levels when compared with age-
matched WT mice (Fig. 2, A–C, respectively). In contrast, the
increased cardiac ANG II in 7-mo-old 2A/2CARKO mice
showed no relation with either cardiac ACE or plasma renin
Table 1. Physiological parameters in wild-type and 2A/2C
ARKO mice
3 mo 7 mo
WT ARKO WT ARKO
No. of mice 12 13 13 11
HR, bpm 555	8 644	8* 569	7 683	8*†
BP, mmHg 113	2 116	2 114	2 111	3
PN, pg/ml 4,682	352 6,044	628* 5,823	673 9,185	865*†
Lung wet/dry ratio 5.1	0.1 5.4	0.2 4.6	0.1 7.6	0.4*†
Distance run, m 402	24 360	26 340	18 254	26*†
Data are presented as means 	 SE. ARKO, 2A and 2C adrenoceptor
knockout; HR, heart rate; BP, blood pressure; PN, plasma noradrenaline. *P 

0.05 vs. wild-type (WT); †P 
 0.05 vs. 3 mo of age.
Fig. 1. Cardiac ANG II (A), cardiac myocyte width (B), and cardiac collagen
volume fraction (C) in 3- and 7-mo-old wild-type (WT, open bars) and 2A and
2C adrenoceptor knockout (ARKO) mice (solid bars). Note that 2A/
2CARKO mice presented elevated cardiac ANG II levels paralleled by an
increased cardiac myocyte cross-sectional diameter. At 7 mo of age, 2A/
2CARKO mice presented ventricular fibrosis. Data are presented as means 	
SE. *P 
 0.05 vs. WT; †P 
 0.05 vs. 3-mo-old mice.
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activities or renal renin expression levels. 2A/2CARKO mice
rather displayed a similar cardiac ACE activity, decreased
plasma renin activity, and renal renin expression levels when
compared with age-matched WT mice (Fig. 2, A–C, respec-
tively).
Because elevated cardiac ANG II in 7-mo-old 2A/
2CARKO mice was not related to activity of cardiac ACE and
plasma renin, we further investigated the cardiac Ao expres-
sion levels in 2A/2CARKO mice. As shown in Fig. 3,
2A/2CARKO mice displayed elevated cardiac Ao gene (Fig.
3A) and protein (Fig. 3B) expression levels when compared
with age-matched WT mice. These results suggest that in-
creased cardiac Ao content is sufficient for cardiac ANG II
formation in 7-mo-old 2A/2CARKO mice regardless reduced
cardiac ACE and plasma renin activities. In fact, cardiac Ao
levels presented a strong correlation with cardiac ANG II
levels (Fig. 3C).
Effect of ARB treatment on left ventricle function and re-
modeling. ARB treatment was used to determine the relative
contribution of RAS activation on cardiac derangements. As
depicted in Fig. 4A, ARB treatment increased FS of 2A/
2CARKO mice to WT values. The improved LV function was
associated with a pronounced anticardiac remodelling effect,
reducing cardiomyocyte width (Fig. 4B), cardiac collagen con-
Fig. 3. Cardiac angiotensinogen (Ao) gene (A) and protein (B) expression
levels and correlation between cardiac angiotensinogen gene expression and
cardiac ANG II levels (C) in 3 and 7 mo-old wild type (WT, open bars) and
2A/2CARKO mice (ARKO, closed bars). Note that 2A/2CARKO mice
presented increased cardiac Ao expression at both gene and protein levels,
which presented a strong correlation with cardiac ANG II levels (r 0.80, P

0.05). Data are presented as means 	 SE. *P 
 0.05 vs. WT.
Fig. 2. Cardiac angiotensin-converting enzyme activity (ACE, A), plasma
renin activity (B) and kidney renin expression (C) in 3 and 7 mo-old wild-type
(WT, open bars) and 2A/2CARKO mice (ARKO, solid bars). Note that
3-mo-old 2A/2CARKO mice presented elevated activity of cardiac ACE and
plasma renin, and increased kidney renin expression. At 7 mo of age, 2A/
2CARKO mice presented cardiac ACE activity similar to age-matched WT
mice but decreased plasma renin activity and renal renin expression. Data are
presented as means 	 SE. *P 
 0.05 vs. WT; †P 
 0.05 vs. 7 mo of age.
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tent (Fig. 4C), LVEDD (3.82 	 0.07, 4.12 	 0.09, and 3.82 	
0.13 mm for WT, placebo-treated 2A/2CARKO, and ARB-
treated 2A/2CARKO mice, respectively; P 
 0.05 vs. WT
and placebo-treated mice), and LVESD (2.99 	 0.06, 3.48 	
0.08, 3.03	 0.09 mm for WT, placebo-treated 2A/2CARKO,
and ARB-treated 2A/2CARKO mice, respectively; P 
 0.05
vs. WT and placebo-treated mice).
DISCUSSION
Sympathetic hyperactivity is a hallmark of progressive heart
failure, and it has been associated with a poor prognosis (4, 12,
35). It is well known that increased sympathetic activity leads
to activation of RAS (9, 36, 37), which ultimately worsens
cardiac function and remodeling. In the present investigation,
we used genetically modified mice based on the disruption of
both 2A and 2C adrenoceptors to study the influence of
sympathetic hyperactivity on the activation of RAS compo-
nents during the progression of cardiac disease and the relative
contribution of RAS to the cardiac structural and functional
abnormalities observed in advanced-stage HF.
The main findings of the present study are that chronic
sympathetic hyperactivity is associated with local RAS activa-
tion and that the deleterious cardiac effects can be counteracted
by ARB treatment. At 3 mo of age, when 2A/2CARKO mice
have preserved exercise tolerance and ventricular function
(27), the increased cardiac ANG II is related to increased
activity of cardiac ACE and plasma renin, as well as an
increased cardiac Ao expression. In contrast, at 7 mo of age,
when 2A/2CARKO mice display exercise intolerance, lung
edema, and ventricular dysfunction, augmented cardiac ANG
II levels rely on the increased cardiac Ao expression levels,
since activity of cardiac ACE and plasma renin is decreased.
It has been previously demonstrated that -AR stimulation
leads to cardiac hypertrophy, which is related to induction of
local RAS (5, 16, 18). In fact, independent cardiac RAS (10,
22) with all RAS components locally expressed (11, 22, 32)
makes RAS more efficient to couple with adrenergic activa-
tion. Our data suggest that cardiac activation of RAS by
sympathetic hyperactivity contributes to the increased cardiac
ANG II levels in 2A/2CARKO mice. This response was
independent of an increase in cardiac afterload since blood
pressure remained unchanged in 2A/2CARKO mice.
As a result of increased cardiac ANG II levels, both 3- and
7-mo-old 2A/2CARKO mice displayed cardiac myocyte hy-
pertrophy. However, a ventricular fibrosis was restricted to
7-mo-old 2A/2CARKO mice. ANG II is recognized for its
hypertrophic and fibrosis effects (7). Our data suggest that at 3
mo of age, sympathetic hyperactivity leads to cardiac myocyte
hypertrophy with no significant cardiac collagen deposition,
which is related to preserved cardiac function and exercise
tolerance, as previously reported (27). With the progression of
cardiomyopathy, as observed in 7-mo-old 2A/2CARKO
mice, cardiac remodeling takes place with cardiac myocyte
hypertrophy and myocardial fibrosis. The latter might in-
volve both increased deposition and altered composition of
extracellular matrix by ANG II via transforming growth
factor and MAPKp42 and MAPKp44 signaling pathways,
which have been previously demonstrated in ANG II-treated
isolated fibroblasts (6).
10
15
20
25
ARKO mice
C
ar
di
ac
 m
yo
cy
te
 w
id
th
(u
m
)
B * †
C
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
C
ar
di
ac
 c
ol
la
ge
n
co
nt
en
t
(%
)
ARKO mice
* †
A
*†
0
5
10
15
20
25
Fr
ac
tio
na
ls
ho
rt
en
in
g
(%
)
WT
mi
ce
Pla
ce
bo
Lo
sa
rta
n
ARKO mice
WT
mi
ce
Pla
ce
bo
Lo
sa
rta
n
WT
mi
ce
Pla
ce
bo
Lo
sa
rta
n
Fig. 4. Left ventricle fractional shortening (FS; A), cardiac myocyte width (B),
cardiac collagen volume fraction (C) in WT and 2A/2CARKO (ARKO) mice
at 7 mo of age. 2A/2CARKO mice were randomly assigned to receive
placebo or ANG II AT1 receptor blocker, losartan, for 8 wk (from 5 to 7 mo
of age). Note that placebo-treated 2A/2CARKO mice presented reduced FS
and increased cardiomyocyte width and cardiac collagen volume fraction vs.
WT mice. Of interest, losartan treatment restored cardiac structure and func-
tion to WT mice values. Data are presented as means 	 SE. *P 
 0.05 vs. WT
mice; †P 
 0.05 vs. ARKO mice treated with losartan.
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The mechanism underlying the increased cardiac ANG II
levels is related to disease stage. At 3 mo of age, 2A/
2CARKO mice presented increased cardiac ACE activity
associated with no changes in ACE gene expression (data not
shown) and augmented plasma renin activity paralleled by an
increased expression of renal renin. Thus, sympathetic hyper-
activity per se (independent of cardiac remodeling and dys-
function) seems to increase cardiac ANG II levels by activating
local RAS components (ACE) and circulating renin. In fact, we
previously demonstrated that increased cardiac ACE activity is
involved in isoproterenol-induced cardiac hypertrophy in rats
(31). In addition, increased cardiac ACE has been also dem-
onstrated in 4-mo-old proto-oncogene Vav3 knockout mice,
which display increased sympathetic activity (37). At 7 mo of
age, 2A/2CARKO mice present cardiac remodeling with
increased fibrosis and cardiac myocyte hypertrophy associated
with a further increase in plasma noradrenaline (see Table 1 for
details) and increased cardiac ANG II. The increased local
ANG II occurred even with decreased local ACE and plasma
renin activities, which suggests that other mechanisms are
taking place in the augmented cardiac ANG II levels. Our data
corroborate that of Heller et al. (17), who found a positive
correlation between plasma renin activity and cardiac hyper-
trophy at 3 days of pressure overload in rats but not at 42 days.
It is also important to highlight the existence of an autocrine/
paracrine RAS (9), which might contribute to the increase in
cardiac ANG II levels in 7-mo-old 2A/2CARKO mice. Re-
cent reports have demonstrated that cardiac mast cells express
renin at mRNA and protein levels (20). When mast cell
degranulation is induced by hyperadrenergic dysfunction, re-
leased renin converts Ao into ANG I (40), and further local
increase of ANG II triggers cardiac arrhythmias (23).
Although circulating levels of Ao have not been assessed,
we speculate that the increase in cardiac ANG II levels are
secondary to augmentation of Ao expression levels, which may
indicate that this is a rate-limiting step for the local increase of
ANG II levels in advanced-stage cardiomyopathy. Indeed,
there was a strong correlation between cardiac Ao expression
and cardiac ANG II, and the ARB treatment counteracted the
cardiac deleterious effects. Furthermore, under normal condi-
tions, low levels of cardiac Ao mRNA and protein levels are
observed (38), which are promptly increased upon cardiac
disease states (24, 41).
In summary, 2A/2CARKO mice at 3 mo of age presented
local and systemic activation of RAS associated with no signs
of HF but increased cardiomyocyte width. In contrast, at 7 mo,
when advanced stage of cardiomyopathy ensued, we detected
only cardiac increases in expression of Ao and ANG II levels.
The cardiac structural and functional abnormalities were coun-
teracted by ARB treatment underscoring the role of local RAS
activation in this process. Taken together, we provided direct
evidence that local RAS activation plays a role in a genetic
model of sympathetic hyperactivity-induced HF in mice.
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